Panelists discuss how the treatment landscape for treatment-naive patients with chronic lymphocytic leukemia (CLL) is rapidly ...

The oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 revealed a manageable safety profile in relapsed ...

An expert discusses emerging real-world strategies for managing adverse effects of antibody-drug conjugates (ADCs) in ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

John L. Marshall, MD, and Marwan G. Fakih, MD, discussed the landscape and sequencing of treatment for refractory colorectal ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Katherine McDaniel, MD, discusses fertility preservation options for patients facing a cancer diagnosis and how the landscape has changed over the past two decades.

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

In an interview with Targeted Oncology, Jacob Sands, MD, medical oncologist at Dana-Farber Cancer Institute, discusses the ...

An expert discusses the evolving management of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), illustrating how CAR T ...

Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.

An expert discusses the multifaceted nature of CAR T-cell therapy for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), emphasizing the need for early multidisciplinary coordination to address ...